These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31956230)

  • 41. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
    Alkabbani W; Gamble JM
    Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
    Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
    J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
    Nisly SA; Kolanczyk DM; Walton AM
    Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
    Hwang YC; Kim JH; Lee BW; Lee WJ
    Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
    Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
    Seufert J
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
    [No Abstract]   [Full Text] [Related]  

  • 54. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
    Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
    Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G
    Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
    Inagaki N; Kondo K; Yoshinari T; Takahashi N; Susuta Y; Kuki H
    Expert Opin Pharmacother; 2014 Aug; 15(11):1501-15. PubMed ID: 25010793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.